This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reply to “The Effects of Newer Antidepressants on Low-Density Lipoprotein Cholesterol Levels”

Linda M. Nicholas, MD, MS; Amy L. Ford, M.A. ;Sharon M. Esposito, MDR; David Ekstrom, MA, MPH; Robert N. Golden, MD

Published: July 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

We appreciate Le Mellédo and colleagues’ interest in our work. Their point is well taken: our 4-week study may not have detected changes in levels of low-density lipoprotein cholesterol (LDL-C) and other lipids that could have reached statistical significance only after 8 or more weeks of mirtazapine exposure. However, we deliberately chose to study healthy control subjects in order to avoid potential confounding effects of a psychiatric disease state per se in our investigation of the effects of mirtazapine. For practical and ethical considerations, we limited the exposure of these healthy subjects to 1 month.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 65

Quick Links: